Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzumab, ibrutinib, and others.
Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and David S. Ettinger, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss the evolution of the NCCN Guidelines, the importance of including palliative care and survivorship recommendations, and the use of the guidelines in community practices.
Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early days of NCCN, controversies that surrounded the first meeting, oncologists’ embrace of the guidelines, and how the organization has evolved over the past 20 years.
Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.
Thomas A. D’Amico, MD, of Duke Cancer Institute, discusses the superior efficacy of thoracoscopic lobectomy. This minimally invasive procedure is used in only 50% of lung cancer surgeries in the United States, in 30% of procedures in Asia, and in as few as 10% to 20% of procedures in Europe.
